NASDAQ: GOVXGeovax Labs Inc Stock
$1.22+0.04 (+3.39%)
Updated Jun 12, 2026
GOVX Price
$1.22
Fair Value Price
$0.71
Market Cap
$4.24M
52 Week Low
$0.96
52 Week High
$34.75
P/E
-0.07x
P/B
8.58x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$21.37M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
5.04
Operating Cash Flow
-$19M
Beta
1.39
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GOVX Overview
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GOVX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GOVX
Ranked#254 of 463
Ranked#254 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.56 | A | |
| $53.13 | A | |
| $15.82 | A |
Be the first to know about important GOVX news, forecast changes, insider trades & much more!
GOVX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GOVX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GOVX ($1.22) is overvalued by 71.17% relative to our estimate of its Fair Value price of $0.71 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GOVX ($1.22) is not significantly undervalued (71.17%) relative to our estimate of its Fair Value price of $0.71 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GOVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GOVX due diligence checks available for Premium users.
Valuation
GOVX fair value
Fair Value of GOVX stock based on Discounted Cash Flow (DCF)
Price
$1.22
Fair Value
$0.71
Overvalued by
71.17%
GOVX ($1.22) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GOVX ($1.22) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GOVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GOVX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.07x
Industry
16.53x
Market
14.15x
GOVX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.58x
Industry
4.85x
GOVX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GOVX's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.3M
Profit Margin
0%
GOVX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$3.0M
Liabilities
$2.5M
Debt to equity
5.04
GOVX's short-term assets ($2.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GOVX's short-term assets ($2.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GOVX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GOVX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.5M
Investing
$0.0
Financing
$1.7M
GOVX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GOVX vs Biotech Stocks
Geovax Labs Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.